Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew E Place

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Cancer Research|March 22, 2003
Synthetic triterpenoids enhance transforming growth factor beta/Smad signalingNanjoo Suh, Anita B Roberts, Stephanie Birkey Reffey, et al.
Pediatric Blood & Cancer|July 17, 2023
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL ConsortiumJennifer J G Welch, Yael Flamand, Kristen E Stevenson, et al.
Haematologica|May 7, 2026
Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemiaAmy Guillaumet-Adkins, Elnaz Mirzaei Mehrabad, Noori Sotudeh, et al.
Cancer Research|June 3, 2005
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingKaren Liby, Thomas Hock, Mark M Yore, et al.
Cancer Medicine|November 27, 2025
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS TumorsDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Blood Advances|July 11, 2023
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trialsShai Shimony, Yael Flamand, Yannis K Valtis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Blood|January 18, 2018
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortiumWeili Sun, Timothy Triche, Jemily Malvar, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Cancer Research|March 22, 2003
Synthetic triterpenoids enhance transforming growth factor beta/Smad signalingNanjoo Suh, Anita B Roberts, Stephanie Birkey Reffey, et al.
Pediatric Blood & Cancer|July 17, 2023
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL ConsortiumJennifer J G Welch, Yael Flamand, Kristen E Stevenson, et al.
Haematologica|May 7, 2026
Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemiaAmy Guillaumet-Adkins, Elnaz Mirzaei Mehrabad, Noori Sotudeh, et al.
Cancer Research|June 3, 2005
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingKaren Liby, Thomas Hock, Mark M Yore, et al.
Cancer Medicine|November 27, 2025
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS TumorsDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Blood Advances|July 11, 2023
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trialsShai Shimony, Yael Flamand, Yannis K Valtis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Blood|January 18, 2018
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortiumWeili Sun, Timothy Triche, Jemily Malvar, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Pageof 6